{
  "ticker": "JNJ",
  "target_date": "2025-10-24",
  "actual_date": "2025-10-24",
  "collected_at": "2025-12-08T12:26:54.783700",
  "price": {
    "open": 190.99,
    "high": 191.1,
    "low": 188.22,
    "close": 189.19873046875,
    "volume": 6903400,
    "change_1d_pct": -1.08,
    "change_7d_pct": -0.4,
    "change_30d_pct": 6.93
  },
  "technicals": {
    "rsi_14": 59.48,
    "sma_20": 188.6,
    "sma_50": 180.97,
    "macd": 3.305,
    "macd_signal": 3.654,
    "macd_histogram": -0.349,
    "bb_upper": 194.72,
    "bb_lower": 182.47,
    "price_vs_sma20_pct": 0.32,
    "price_vs_sma50_pct": 4.55,
    "volume_ratio": 0.8
  },
  "fundamentals": {
    "market_cap": 487496777728,
    "pe_ratio": 19.530888,
    "forward_pe": 19.088678,
    "price_to_book": 6.141379,
    "price_to_sales": 5.29031,
    "profit_margin": 27.26,
    "operating_margin": 30.2,
    "roe": 33.62,
    "roa": 8.26,
    "revenue_growth": 6.8,
    "earnings_growth": 91.0,
    "debt_to_equity": 57.766,
    "current_ratio": 1.074,
    "quick_ratio": 0.711,
    "dividend_yield": 258.0,
    "fifty_two_week_high": 207.81,
    "fifty_two_week_low": 140.68,
    "fifty_day_avg": 193.4922,
    "two_hundred_day_avg": 170.2741,
    "analyst_target": 203.41833,
    "analyst_recommendation": "buy",
    "num_analysts": 24,
    "sector": "Healthcare",
    "industry": "Drug Manufacturers - General",
    "pct_from_52w_high": -2.63,
    "pct_from_52w_low": 43.83
  },
  "macro": {
    "spy": {
      "price": 677.25,
      "change_1d_pct": 0.82,
      "change_7d_pct": 2.51
    },
    "vix": {
      "level": 16.37,
      "signal": "NORMAL"
    },
    "treasury_10y": {
      "yield_pct": 4.0
    },
    "dollar_index": {
      "level": 98.95
    },
    "gold": {
      "price": 4118.4
    },
    "regime": "BULL_LOW_VOL"
  },
  "news": [
    {
      "headline": "Published in The Lancet: Nipocalimab significantly decreased Sj\u00f6gren's disease (SjD) activity and severity through substantial reduction in Sj\u00f6gren's-related autoantibodies",
      "source": "Yahoo",
      "datetime": 1761345120,
      "summary": "Johnson & Johnson (NYSE: JNJ) today announced findings from the Phase 2 DAHLIAS study published in The Lancet showing that nipocalimab, an investigational FcRn treatment for Sj\u00f6gren's disease (SjD), significantly decreased disease activity and severity in patients with moderate-to-severe disease.1",
      "url": "https://finnhub.io/api/news?id=c86fb7f8ae95bffdf41e3b7ce4ab943935b5e44e9634f5d5c1ad3fc94d254ae4"
    },
    {
      "headline": "GSK Crumbles As Blood Cancer Comeback Falls Unexpectedly Short",
      "source": "Yahoo",
      "datetime": 1761336770,
      "summary": "GSK stock crumbled Friday after the FDA granted its blood cancer treatment, Blenrep, a narrower-than-expected approval.",
      "url": "https://finnhub.io/api/news?id=81411fc6099e1c4fca23e207cfc1979aa83ee43b1525337576aa3dcd1571558f"
    },
    {
      "headline": "Trade Truce Hope: How US-China Talks Could Boost Healthcare ETFs",
      "source": "Yahoo",
      "datetime": 1761319860,
      "summary": "Hopes of a U.S.-China trade truce are lifting sentiment for healthcare ETFs like XLV, IYH, and VHT, which could gain from easing tariffs and lower costs.",
      "url": "https://finnhub.io/api/news?id=fef1e73965e5b9794217b3c7ef7483d653b03c44ce7e464915489e38b2911be2"
    },
    {
      "headline": "Merck's Non-Oncology Drugs Q3 Performance: What to Expect",
      "source": "Yahoo",
      "datetime": 1761314700,
      "summary": "MRK expects new products like Capvaxive, Winrevair, and the Animal Health business to support its top-line growth in the third quarter.",
      "url": "https://finnhub.io/api/news?id=a495ba94edf3b314d66e89597bef0a858857553e06dd26275f1c5513e830a084"
    },
    {
      "headline": "Icotrokinra long-term results affirm promise of targeted oral peptide with high rates of durable skin clearance and favorable safety profile in difficult-to-treat scalp and genital psoriasis",
      "source": "Yahoo",
      "datetime": 1761307200,
      "summary": "Johnson & Johnson (NYSE: JNJ) today announced new long-term 52-week data from the Phase 3 ICONIC-TOTAL studya evaluating icotrokinra, a first-in-class investigational targeted oral peptide that precisely blocks the IL-23 receptor, in adults and pediatric patients 12 years of age and older (adolescen",
      "url": "https://finnhub.io/api/news?id=2a650b12f5fbf8d4873f4b4c06d2a880d87e2cbe068ff9c6311bc998f19e2283"
    }
  ],
  "news_count": 5,
  "sec_filings": [
    {
      "form": "10-Q",
      "date": "2025-10-22",
      "description": "jnj-20250928.htm",
      "url": "https://www.sec.gov/Archives/edgar/data/200406/000020040625000209/jnj-20250928.htm"
    },
    {
      "form": "4",
      "date": "2025-10-20",
      "description": "xslF345X05/wk-form4_1761002033.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/200406/000020040625000204/xslF345X05/wk-form4_1761002033.xml"
    },
    {
      "form": "8-K",
      "date": "2025-10-14",
      "description": "jnj-20251014.htm",
      "url": "https://www.sec.gov/Archives/edgar/data/200406/000020040625000201/jnj-20251014.htm"
    },
    {
      "form": "4",
      "date": "2025-09-11",
      "description": "xslF345X05/wk-form4_1757627547.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/200406/000020040625000196/xslF345X05/wk-form4_1757627547.xml"
    },
    {
      "form": "4",
      "date": "2025-09-11",
      "description": "xslF345X05/wk-form4_1757627315.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/200406/000020040625000194/xslF345X05/wk-form4_1757627315.xml"
    }
  ],
  "sec_filings_count": 5,
  "data_quality": {
    "has_price": true,
    "has_technicals": true,
    "has_fundamentals": true,
    "has_macro": true,
    "has_news": true,
    "has_sec_filings": true
  }
}